Scolaris Content Display Scolaris Content Display

Search strategy of CBM
Figures and Tables -
Figure 1

Search strategy of CBM

Search strategy of CNKI
Figures and Tables -
Figure 2

Search strategy of CNKI

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figures and Tables -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figures and Tables -
Figure 4

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 1 Number of participants with relapses at 9 months.
Figures and Tables -
Analysis 1.1

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 1 Number of participants with relapses at 9 months.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 2 Number of participants with relapses at 12 months.
Figures and Tables -
Analysis 1.2

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 2 Number of participants with relapses at 12 months.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 3 Number of participants with relapses at 24 months.
Figures and Tables -
Analysis 1.3

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 3 Number of participants with relapses at 24 months.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 4 Number of participants with relapses.
Figures and Tables -
Analysis 1.4

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 4 Number of participants with relapses.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 5 Number of participants with relapses of different doses.
Figures and Tables -
Analysis 1.5

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 5 Number of participants with relapses of different doses.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 6 Number of participants with disease progression.
Figures and Tables -
Analysis 1.6

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 6 Number of participants with disease progression.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 7 Number of participants with new T2 or GELs at 9 months.
Figures and Tables -
Analysis 1.7

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 7 Number of participants with new T2 or GELs at 9 months.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 8 Number of participants with new T2 or GELs at 12 months.
Figures and Tables -
Analysis 1.8

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 8 Number of participants with new T2 or GELs at 12 months.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 9 Number of participants with new T2 or GELs.
Figures and Tables -
Analysis 1.9

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 9 Number of participants with new T2 or GELs.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 10 Number of participants with new T2 or GELs of different doses.
Figures and Tables -
Analysis 1.10

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 10 Number of participants with new T2 or GELs of different doses.

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 11 Changes of EDSS score at 24 months.
Figures and Tables -
Analysis 1.11

Comparison 1 Atorvastatin plus beta interferon versus beta interferon, Outcome 11 Changes of EDSS score at 24 months.

Comparison 1. Atorvastatin plus beta interferon versus beta interferon

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of participants with relapses at 9 months Show forest plot

1

26

Risk Ratio (M‐H, Fixed, 95% CI)

2.12 [0.28, 16.24]

2 Number of participants with relapses at 12 months Show forest plot

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.45, 2.23]

3 Number of participants with relapses at 24 months Show forest plot

1

45

Risk Ratio (M‐H, Fixed, 95% CI)

0.70 [0.36, 1.36]

4 Number of participants with relapses Show forest plot

2

71

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.45, 1.57]

5 Number of participants with relapses of different doses Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 20 mg/d atorvastatin

1

45

Risk Ratio (M‐H, Fixed, 95% CI)

0.70 [0.36, 1.36]

5.2 40 mg/d atorvastatin

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

2.57 [0.29, 22.93]

5.3 80 mg/d atorvastatin

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

1.8 [0.19, 16.66]

6 Number of participants with disease progression Show forest plot

1

45

Risk Ratio (M‐H, Fixed, 95% CI)

0.13 [0.01, 2.22]

7 Number of participants with new T2 or GELs at 9 months Show forest plot

1

26

Risk Ratio (M‐H, Fixed, 95% CI)

4.24 [0.62, 28.76]

8 Number of participants with new T2 or GELs at 12 months Show forest plot

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.30, 3.36]

9 Number of participants with new T2 or GELs Show forest plot

2

60

Risk Ratio (M‐H, Fixed, 95% CI)

1.80 [0.66, 4.86]

10 Number of participants with new T2 or GELs of different doses Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 20 mg/d atorvastatin

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.30, 3.36]

10.2 40 mg/d atorvastatin

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

3.86 [0.50, 29.55]

10.3 80 mg/d atorvastatin

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

4.5 [0.64, 31.60]

11 Changes of EDSS score at 24 months Show forest plot

1

45

Mean Difference (IV, Fixed, 95% CI)

‐0.2 [‐0.84, 0.44]

Figures and Tables -
Comparison 1. Atorvastatin plus beta interferon versus beta interferon